Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis
Sigrid Machherndl‐Spandl(Krankenhaus der Elisabethinen), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Gerald Webersinke(AGO Austria), Emine Kaynak(Krankenhaus der Elisabethinen), Christine Gruber-Rossipal, Holger Rumpold(Innsbruck Medical University), Eva Maier(Kepler Universitätsklinikum), Irene Straßl(Krankenhaus der Elisabethinen), Wolfgang Schimetta(Johannes Kepler University of Linz), Johannes Clausen(Johannes Kepler University of Linz), Veronika Sygulla(Johannes Kepler University of Linz), Christine Beham‐Schmid(Medical University of Graz), Alexander Nikoloudis(Johannes Kepler University of Linz), Marcel Kiehberger(Johannes Kepler University of Linz), Otto Zach(Kepler Universitätsklinikum)
Cited by 1
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
|Blood Cancer Journal|2015|273